Welcome to our dedicated page for ALPHA COGNITION NEW news (Ticker: ACOGF), a resource for investors and traders seeking the latest updates and insights on ALPHA COGNITION NEW stock.
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) is a clinical-stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases. The company is primarily focused on addressing conditions like Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), which currently lack approved treatment options.
Alpha Cognition's flagship product, ALPHA-1062, is a patented new chemical entity in development as a next-generation acetylcholinesterase inhibitor for the treatment of mild-to-moderate Alzheimer’s disease. Designed to minimize gastrointestinal side effects, ALPHA-1062's active metabolite is differentiated from existing therapies like donepezil and rivastigmine. The compound binds to neuronal nicotinic receptors, notably the alpha-7 subtype, which is known to positively affect cognition. ALPHA-1062 is also being developed in combination with memantine for moderate to severe Alzheimer’s dementia and as an intranasal formulation for Cognitive Impairment with mTBI.
In recent developments, Alpha Cognition has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALPHA-1062, with an expected approval date in the second half of 2024. This milestone underscores the company's commitment to advancing patient care and highlights their robust pipeline of innovative treatments.
Alpha Cognition has also received significant recognition in the form of patents and grants. The company was recently awarded a $750,000 research and development grant from the U.S. Department of Defense to study ALPHA-1062's potential in treating mTBI. Additionally, the company holds multiple patents for ALPHA-1062, including a new composition-of-matter patent that extends protection into 2044.
The company's financial strategy includes successfully raising gross proceeds of $8.45 million through private placements, which will be used for research and development, general and administrative matters, and working capital. This funding is crucial for furthering the development and potential commercialization of their lead product, ALPHA-1062.
Alpha Cognition's commercialization strategy aims to initially target the Long Term Care (LTC) market, followed by the broader Neurology segment once payer reimbursement is established. This approach is expected to maximize the impact of ALPHA-1062 in the Alzheimer’s treatment landscape.
Overall, Alpha Cognition Inc. is poised for a transformational year with significant advancements in their pipeline, financial health, and strategic positioning to bring innovative therapies to market for neurodegenerative diseases.
Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF), a biopharmaceutical company focused on therapies for neurodegenerative disorders, announces the anticipated completion of the second tranche of its private placement offering before March 17, 2023. The company is developing ALPHA-1062, a new acetylcholinesterase inhibitor for Alzheimer's treatment, promising minimal gastrointestinal side effects and improved cognitive support. Alpha Cognition emphasizes that this news does not constitute a sale offer in the U.S., where the securities remain unregistered under the 1933 Act.
Alpha Cognition Inc. has successfully closed the first tranche of its private placement, issuing 16,795,221 units at
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced a private placement financing aiming for gross proceeds of up to
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced the cancellation of 4,655,000 incentive stock options priced between
Alpha Cognition Inc. (ACOGF) announced the resignation of Chief Medical Officer, Cedric O’Gorman, who is leaving to pursue other opportunities. The company is actively seeking a replacement while maintaining strong consultant relationships for its upcoming NDA filing for ALPHA-1062, targeting Alzheimer’s Disease. CEO Michael McFadden praised Dr. O’Gorman’s contributions, particularly in achieving positive results for ALPHA-1062. The NDA filing is expected in 2023, indicating a significant step forward for the company in addressing neurodegenerative disorders.
Alpha Cognition (ACOGF) has reported its financial results for Q3 2022, emphasizing preparations for filing a New Drug Application (NDA) for ALPHA-1062, a potential oral therapy for mild to moderate Alzheimer's disease. The company withdrew a previously announced public offering, citing unfavorable market conditions. R&D expenses rose to $1.6 million in Q3, while G&A expenses increased to $0.9 million. The net loss was $2.8 million, a decrease from $4.3 million in Q3 2021. As of September 30, 2022, cash reserves stood at $3.7 million with 61,023,450 shares outstanding.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF), a biopharmaceutical company focusing on neurodegenerative disorders, reported its Q2 2022 financial results. Highlights include positive topline data from the ALPHA-1062 pivotal trial, which supports an NDA filing scheduled for Q2 2023. The RESOLVE trial, assessing ALPHA-1062's tolerability in Alzheimer's patients, is set to initiate soon. The company is actively seeking funding and implementing cost-cutting measures to extend its cash runway, with $6.0 million available as of June 30, 2022, and a net loss of $3.4 million for the quarter.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced successful results from a bioequivalence study of ALPHA-1062, a delayed release oral tablet for treating mild to moderate Alzheimer’s Disease (AD). The study confirmed ALPHA-1062's equivalency to galantamine hydrobromide formulations, with significant pharmacokinetic results. The data strengthens the forthcoming NDA application, planned for Q2 2023. The Chief Medical Officer highlighted the potential of ALPHA-1062 to limit gastrointestinal side effects, aiming to improve treatment for AD patients.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced positive results from its pivotal bioequivalence study of ALPHA-1062, a delayed release oral tablet for treating mild to moderate Alzheimer's Disease. The study showed pharmacokinetic equivalence to the reference drug galantamine hydrobromide, with no adverse events reported. The company aims to file a New Drug Application (NDA) in Q2 2023. ALPHA-1062 offers a potentially effective treatment option by minimizing gastrointestinal side effects common with current therapies.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has announced that the European Patent Office confirmed the patentability of EP3009143, related to treating neurodegenerative diseases, following an opposition proceeding. The patent covers a composition that increases progranulin expression, which is linked to motor neuron disease. This complements another patent for treating Alzheimer's and Parkinson's. Additionally, the company has received Orphan Drug Designation for ALPHA-0602, aimed at treating ALS, granting seven years of market exclusivity upon approval.
FAQ
What is the current stock price of ALPHA COGNITION NEW (ACOGF)?
What is the market cap of ALPHA COGNITION NEW (ACOGF)?
What is Alpha Cognition Inc.?
What is ALPHA-1062?
What recent milestone has Alpha Cognition achieved?
What are the financial highlights for Alpha Cognition?
What is the commercialization strategy for ALPHA-1062?
What grants and patents has Alpha Cognition received?
How does ALPHA-1062 differ from other treatments?
What is the potential market size for ALPHA-1062?
What is the significance of the new composition-of-matter patent for ALPHA-1062?
Who is the CEO of Alpha Cognition?
